Stocks Health care ENSC
NASDAQ · Health careEnsysce Biosciences, Inc. (ENSC)
Ensysce Biosciences, Inc. brought in $4.5M of revenue over the twelve months to June 30, 2026, down 39.3% from a year earlier. It posted a net loss of $12.6M. In fiscal 2025 capital spending exceeded operating cash flow by $7.9M. At June 30, 2026 it held $676.7K in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 13, 2026.
Key facts about Ensysce Biosciences, Inc.
- Net worth
- Ensysce Biosciences, Inc. has a market value (market cap) of $7M at the latest share price, and shareholders' equity of -$781.7K on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $5.1M (-2.8% year on year), with a net loss of $10.2M. Over the 12 months to June 30, 2026: revenue $4.5M, net loss $12.6M.
- Cash flow
- In fiscal 2025 operations used $7.8M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 13, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Ensysce Biosciences, Inc.'s next report is expected around November 13, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
What Ensysce Biosciences, Inc. does
Ensysce Biosciences, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker ENSC.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $5.1M | -$10.2M | -$3.98 | -$7.9M |
| 2024 | $5.2M | -$8M | -$11.45 | n/a |
| 2023 | $2.2M | -$10.6M | -$70.40 | n/a |
| 2022 | $2.5M | -$25.1M | -$2,092.79 | n/a |
| 2021 | $3.5M | -$29.9M | -$22.22 | n/a |
| 2020 | $3.9M | $4.3M | $0.00 | n/a |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where ENSC ranks in Health care
Latest SEC filings
What Ensysce Biosciences, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 29, 2026
- August 25, 2026Other event 8-K
- August 24, 2026Other event 8-K
- August 18, 2026Activist stake changed SCHEDULE 13D/A
- August 13, 2026Quarterly report 10-Q · period to June 30, 2026Revenue fell 15% to $1.2M versus the same quarter last year; diluted EPS -$0.20 versus -$0.79.
- August 13, 2026
- August 6, 2026Exhibits 8-K/A
- August 6, 2026
- July 15, 2026
- June 4, 2026
Insider trades
What the people running Ensysce Biosciences, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| August 7, 2026 | Gower Bob GDirector | Bought | 400,000 | $198K |
| April 23, 2026 | Gower Bob GDirector | Bought | 508,614 | $246.2K |
Who owns ENSC
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Bob Gene Gower13D, may seek influence | 6.1% | August 18, 2026 |
Largest institutional holders
Insiders
1 insiders reported holding 916,740 shares in total, about $330K at the last price.
| Holder | Shares |
|---|---|
| Gower Bob GDirector | 916,740 |
Questions about ENSC
What does Ensysce Biosciences, Inc. do?
Ensysce Biosciences, Inc. is a company in the Health care sector, listed on NASDAQ as ENSC. Its shares trade on NASDAQ under the ticker ENSC.
What is Ensysce Biosciences, Inc.'s net worth?
Ensysce Biosciences, Inc. has a market value (market cap) of $7M at the latest share price, and shareholders' equity of -$781.7K on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Ensysce Biosciences, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $12.6M on revenue of $4.5M.
How much revenue does Ensysce Biosciences, Inc. make?
Over the twelve months to June 30, 2026 Ensysce Biosciences, Inc. reported revenue of $4.5M. That is 39.3% less than a year earlier.
When did Ensysce Biosciences, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 13, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the bylaws or fiscal year changed from September 29, 2026.
When is Ensysce Biosciences, Inc.'s next earnings report?
Ensysce Biosciences, Inc.'s next report is expected around November 13, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare ENSC with
Follow ENSC
Get an email when Ensysce Biosciences, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Ensysce Biosciences, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.